Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Authors

• Narendranath Epperla, The Ohio State University
• Qiuhong Zhao, The Ohio State University
• Sayan Mullick Chowdhury, The Ohio State University
• Lauren Shea, Washington University
• Tamara K. Moyo, Levine Cancer Center
• Nishitha Reddy, Vanderbilt University Medical Center
• Julia Sheets, University of North Carolina
• David M. Weiner, University of Pennsylvania
• Praveen Ramakrishnan Geethakumari, University of Texas Southwestern Medical Center
• Malathi Kandarpa, University of Michigan
• Ximena Jordan Bruno, University of Vermont
• Colin Thomas, Thomas Jefferson UniversityFollow
• Michael C. Churnetski, Emory University Medical Center
• Andrew Hsu, Brown University
• Luke Zurbriggen, University of Wisconsin
• Xiao-Wei Cherie Tan, Cancer Institute of New Jersey
• Kathryn Lindsey, Medical University of South Carolina
• Joseph Maakaron, University of Minnesota
• Paolo F. Caimi, University Hospitals Seidman Cancer Center
• Pallawi Torka, Roswell Park Cancer Institute
• Celeste Bello, H. Lee Moffitt Cancer Center and Research Institute
• Sabarish Ayyappan, University of Iowa
• Timothy S. Oh, Northwestern University
• Reem Karmali, Northwestern University
• Seo-Hyun Kim, Rush University
• Anna Kress, Yale University
• Shalin Kothari, Yale University
• Yazeed Sawalha, The Ohio State University
• Beth Christian, The Ohio State University
• Kevin A. David, Cancer Institute of New Jersey
• Irl Brian Greenwell, Medical University of South Carolina
• Murali Janakiram, University of Michigan
• Vaishalee P. Kenkre, University of Wisconsin
• Adam J. Olszewski, Brown University
• Jonathon B. Cohen, Emory University Medical Center
• Neil Palmisiano, Thomas Jefferson University
• Elvira Umyarova, University of Vermont
• Ryan A. Wilcox, University of Michigan
• Farrukh T. Awan, University of Texas Southwestern Medical Center
• Juan Pablo Alderuccio, University of Miami
• Stefan K. Barta, University of Pennsylvania
• Natalie S. Grover, University of North Carolina
• Nilanjan Ghosh, Levine Cancer Center
• Nancy L. Bartlett, Washington University
• Alex F. Herrera, Washington University
• Geoffrey Shouse, City of Hope Medical Center

Document Type

Letter to the Editor

Publication Date

1-10-2023

Comments

This research letter is the author's final published version in Blood Advances, Volume 7, Issue 1, January 2023, Pg. 88 - 91.

The published version is available at https://doi.org/10.1182/bloodadvances.2022008634. Copyright © 2022 by The American Society of Hematology.

Recommended Citation

Epperla, Narendranath; Zhao, Qiuhong; Chowdhury, Sayan Mullick; Shea, Lauren; Moyo, Tamara K.; Reddy, Nishitha; Sheets, Julia; Weiner, David M.; Geethakumari, Praveen Ramakrishnan; Kandarpa, Malathi; Bruno, Ximena Jordan; Thomas, Colin; Churnetski, Michael C.; Hsu, Andrew; Zurbriggen, Luke; Tan, Xiao-Wei Cherie; Lindsey, Kathryn; Maakaron, Joseph; Caimi, Paolo F.; Torka, Pallawi; Bello, Celeste; Ayyappan, Sabarish; Oh, Timothy S.; Karmali, Reem; Kim, Seo-Hyun; Kress, Anna; Kothari, Shalin; Sawalha, Yazeed; Christian, Beth; David, Kevin A.; Greenwell, Irl Brian; Janakiram, Murali; Kenkre, Vaishalee P.; Olszewski, Adam J.; Cohen, Jonathon B.; Palmisiano, Neil; Umyarova, Elvira; Wilcox, Ryan A.; Awan, Farrukh T.; Alderuccio, Juan Pablo; Barta, Stefan K.; Grover, Natalie S.; Ghosh, Nilanjan; Bartlett, Nancy L.; Herrera, Alex F.; and Shouse, Geoffrey, "Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma" (2023). Department of Medicine Faculty Papers. Paper 401.
https://jdc.jefferson.edu/medfp/401

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

36269847

Language

English